Latest DexCom Inc News and Updates
Tandem Diabetes Care Rallies on FDA Approval of Insulin Pump
Today, Tandem Diabetes Care (TNDM) opened~16.2% higher than yesterday’s closing price of $20.31, triggered by the news of FDA approval of its t:slim X2 insulin pump with Basal IQ technology.
Tandem Diabetes Care’s International Expansion Strategy
Tandem Diabetes Care (TNDM) is slated to begin its international expansion later this year to capture opportunities arising after Johnson & Johnson’s (JNJ) exit from the insulin pump market, which was announced in October 2017.
Diabetes Management Breakthrough: Medtronic’s MiniMed 670G
On June 7, 2017, Medtronic (MDT) announced the launch of MiniMed 670G—the world’s first HCL (hybrid closed loop) insulin delivery system.
Tandem Diabetes Care’s Stock Performance This Month
On June 26, Tandem Diabetes Care (TNDM) ended the trading day at $23.64, ~7.3% lower than its 52-week low of $25.50 reached on June 22, triggered by news of the FDA’s approval of the company’s new insulin pump.
Abbott’s Freestyle Libre Gets Reimbursement Approval in France
Abbott Laboratories’ (ABT) Freestyle Libre is a sensor-based continuous glucose monitoring system that monitors and evaluates glucose levels up to 14 days.
Tandem Diabetes Care Stock Has Skyrocketed in 2018
On November 21, Tandem Diabetes Care stock closed at $32.63, a ~14.69% rise from its previous day’s close of $28.45.
Why Wall Street Is Still Bullish on Tandem Stock
This month, of the total ten analysts covering Tandem Diabetes Care (TNDM), seven have given the stock a “buy” or higher rating and three have given it a “hold” rating.
Why Tandem Should Be on Your Stock Radar
Tandem Diabetes Care’s (TNDM) key focus is its t:slim X2 insulin delivery system, which is designed to display continuous glucose monitoring directly on a pump’s home screen.
A Look into Johnson & Johnson’s Diabetes Care Business
In the US and international markets, Johnson & Johnson’s Diabetes Care segment generated third-quarter net revenues of $125.0 million and $190.0 million, respectively.
What to Expect from Tandem’s Product Pipeline
T:sport is Tandem’s next-generation hardware platform, which is expected to reduce the size of the t:slim pump by 50%.
FDA Approves Arm Indication for Medtronic’s Guardian Sensor 3
On February 26, 2018, Medtronic (MDT) announced that the FDA has approved a new arm indication for its Guardian Sensor 3.
Medtronic Strengthens Diabetes Business with MiniMed Infusion Set
On February 21, 2018, Medtronic (MDT) announced the launch of its MiniMed Mio Advance infusion set.
Abbott’s Breakthrough CGM Device Freestyle Libre Wins FDA Approval
On September 27, Abbott Laboratories (ABT) announced the FDA approval of its Flash CGM (continuous glucose monitoring) device, Freestyle Libre.
What Explains the Columbia Select Large Cap Growth Fund’s Poor Showing?
The short-term performance of the Columbia Select Large Cap Growth Fund – Class A (ELGAX) is excellent, and the past six months have been great for the fund.
Johnson & Johnson’s Latest Medical Device Launches
Johnson & Johnson has announced the schedule for the launch of the OneTouch Via insulin patch. It plans to launch the device in select US markets by the end of 2016.